Tag Archives: S&P/ASX 200 S&P/ASX 300 ALL ORDINARIES S&P/ASX SMALL ORDINARIES S&P/ASX All Australian 200 S&P/ASX 200 Health Care

Japara Healthcare Ltd (ASX: JHC) has bought four new land purchases in FY17 and built 445 new greenfield beds in the anticipation.

Japara Healthcare Ltd (ASX: JHC) has bought four new land purchases in FY17 and built 445 new greenfield beds in the anticipation. During H1FY17, JHC had reported a revenue growth of 14.5% year on year (yoy) to $178.5 million while EBITDA grew by 3.6% yoy to $29.1 million. However, it has witnessed a decline of 9.9% yoy in net profit

Read more

2 ways you can profit from Australia’s ageing population – Japara Healthcare and Ramsay Health care

Japara Healthcare Ltd (ASX: JHC) has bought four new land purchases in FY17 and built 445 new greenfield beds in the anticipation. During H1FY17, JHC had reported a revenue growth of 14.5% year on year (yoy) to $178.5 million while EBITDA grew by 3.6% yoy to $29.1 million. However, it has witnessed a decline of 9.9% yoy in net profit

Read more

One pharmaceutical company to buy – Australian Pharmaceutical Industries Ltd.

Australian Pharmaceutical Industries Limited (API) today reported NPAT of $29.1m for the six months to 28 February 2017, an underlying increase of 15% on the pcp. Reported NPAT was 27.2% up on the pcp, which included a $2.4m loss on the sale of API’s shareholding in CH2 in the pcp. The company has increased NPAT and returns to shareholders through

Read more

Recently, Sirtex Medical Limited presented the SIRFLOX/FOXFIRE Global right-side survival data in metastatic colorectal cancer (MCRC)

Recently, Sirtex Medical Limited (ASX:SRX) presented the SIRFLOX/FOXFIRE Global right-side survival data in metastatic colorectal cancer (mCRC) at the 19th European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer (WCGIC) in Barcelona, Spain. The combined SIRFLOX and FOXFIRE Global studies (n=530 and n=209, respectively) showed that for patients with a right-sided primary tumor, median Overall Survival (OS) was

Read more

One Biotechnology Stock to buy – Sirtex Medical Limited

Reiterated FY17 guidance: Shares of Sirtex Medical Limited (ASX: SRX) zoomed 16.16%, after the announcement of its full year guidance for FY17 and write down of R&D assets. SRX expects 5.5% yoy overall growth in worldwide dose sales at approximately 12,590 and underlying EBITDA of $72 million for FY17. Further, across the three regions, it estimates 4.7% yoy growth in

Read more

One expensive Healthcare stock – Japara Healthcare Ltd

Japara Healthcare Ltd (ASX: JHC) is aiming to attain a better position in the industry in order to leverage the growing demand at the back of increase in ageing population. The Cumulative Average Growth Rate of government funding during the fiscal 2008 to 2015 period was 8.6% and the government funding has been expected to rise going forward as ACFA estimates

Read more

Mesoblast Limited Positive Update On Heart

Positive update on heart failure trial and funding drove the stock: Mesoblast limited (ASX: MSB) stock surged over 15.34% on July 01, 2016 driven by the group’s update on heart failure trial and funding of its clinical operations. The group reported that their interim analysis would evaluate the heart failure Phase 3 trial’s primary endpoint to give meaningful data in

Read more
« Older Entries